Treatment of Multiple Sclerosis in Highly Active Disease
Patients with highly active multiple sclerosis represent a distinct clinical population requiring a targeted treatment approach. This protocol addresses disease-modifying therapy selection in the context of highly active MS.
Clinical scenario
The patient presents with highly active multiple sclerosis — a sub-population in which the level of disease activity shapes the choice of therapy and the urgency of intervention.
Treatment approach
Evidence supports prescribing specific high-efficacy disease-modifying agents for patients in this category — agents such as alemtuzumab are among those recommended at a Level B evidence grade.
The complete therapy selection, sequencing, and clinical criteria are available in the full protocol below.
References
DOI: 10.1212/WNL.0000000000005347
Clinicians should prescribe alemtuzumab, fingolimod, or natalizumab for people with MS with highly active MS (Level B).
View source ↗